According to a recent LinkedIn post from Parallel Fluidics, the company is promoting on-site demonstrations of its LNP Screening Array for local biopharma customers in the Boston area. The post indicates that Parallel Fluidics is willing to deploy its system directly on a customer’s existing liquid handler to showcase automated lipid nanoparticle formulation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that it will provide live demos with customer teams and supply Starter Arrays to support initial screening campaigns at no extra cost. This outreach suggests a targeted customer acquisition effort in a geographically dense biotech hub, which could help accelerate adoption, generate recurring consumables revenue, and strengthen the firm’s position in the growing LNP and lab automation markets.